Publications by authors named "Rachel M Tallman"
Background: Cancer metastasis and drug resistance have traditionally been studied separately, though these two lethal pathological phenomena almost always occur concurrently. Brain metastasis occurs in a large proportion of lung cancer patients (~ 30%). Once diagnosed, patients have a poor prognosis surviving typically less than 1 year due to lack of treatment efficacy.
View Article and Find Full Text PDFBackground: Brain tumor vasculature can be significantly compromised and leakier than that of normal brain blood vessels. Little is known if there are vascular permeability alterations in the brain adjacent to tumor (BAT). Changes in BAT permeability may also lead to increased drug permeation in the BAT, which may exert toxicity on cells of the central nervous system.
View Article and Find Full Text PDFArticle Synopsis
- * Current treatments for breast cancer brain metastases (BCBM) include surgery, radiation, and chemotherapy, but they often don't significantly improve survival and are mainly palliative.
- * Recent advancements in chemotherapy have introduced new targeting agents and formulations, like PARP inhibitors and nanoparticles, which show promise and are being tested in ongoing clinical trials to improve treatment outcomes for BCBM.